BE888073A - DERIVES D'IMIDAZO 4,5-b PYRIDINE LEUR PREPARATION ET LEUR UTILISATION COMME AGENTS CARDIOTONIQUES. - Google Patents

DERIVES D'IMIDAZO 4,5-b PYRIDINE LEUR PREPARATION ET LEUR UTILISATION COMME AGENTS CARDIOTONIQUES.

Info

Publication number
BE888073A
BE888073A BE1/10185A BE1010185A BE888073A BE 888073 A BE888073 A BE 888073A BE 1/10185 A BE1/10185 A BE 1/10185A BE 1010185 A BE1010185 A BE 1010185A BE 888073 A BE888073 A BE 888073A
Authority
BE
Belgium
Prior art keywords
imidazo
preparation
pyridine derivatives
cardiotonic agents
cardiotonic
Prior art date
Application number
BE1/10185A
Other languages
English (en)
Inventor
Derives D Imidazo
B Pyridine
Original Assignee
Sterling Drug Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Drug Inc filed Critical Sterling Drug Inc
Publication of BE888073A publication Critical patent/BE888073A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BE1/10185A 1980-03-24 1981-03-23 DERIVES D'IMIDAZO 4,5-b PYRIDINE LEUR PREPARATION ET LEUR UTILISATION COMME AGENTS CARDIOTONIQUES. BE888073A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/132,907 US4294836A (en) 1980-03-24 1980-03-24 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use

Publications (1)

Publication Number Publication Date
BE888073A true BE888073A (fr) 1981-09-23

Family

ID=22456117

Family Applications (1)

Application Number Title Priority Date Filing Date
BE1/10185A BE888073A (fr) 1980-03-24 1981-03-23 DERIVES D'IMIDAZO 4,5-b PYRIDINE LEUR PREPARATION ET LEUR UTILISATION COMME AGENTS CARDIOTONIQUES.

Country Status (5)

Country Link
US (1) US4294836A (fr)
JP (1) JPS56150089A (fr)
KR (1) KR830005216A (fr)
BE (1) BE888073A (fr)
ZA (1) ZA811903B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5881033U (ja) * 1981-11-28 1983-06-01 日本軽金属株式会社 プレス型用クランプ装置
WO2008030408A2 (fr) * 2006-09-05 2008-03-13 Yale University Composés protéomimétiques inhibant l'interaction d'un récepteur nucléaire avec des peptides de coactivateur
ES2627352T3 (es) * 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
CN103998036B (zh) 2011-10-19 2017-05-31 西格诺药品有限公司 利用tor激酶抑制剂治疗癌症
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
CN104271159B (zh) 2012-02-24 2017-11-28 西格诺药品有限公司 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CA2908742C (fr) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Polytherapie comprenant un inhibiteur de la kinase tor et un analogue de la cytidine pour le traitement du cancer
WO2014172425A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Traitement du cancer par des dihydropyrazino-pyrazines
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ,エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
EP3549940A1 (fr) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Formulations pharmaceutiques associés à 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172436A1 (fr) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Polythérapie comprenant un inhibiteur de kinase tor et un composé de quinazolinone substitué en 5 pour le traitement du cancer
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131552B1 (fr) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Méthodes de traitement du cancer à l'aide d'une polythérapie avec des inhibiteurs de la kinase tor
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
WO2015160880A1 (fr) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016010886A1 (fr) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Méthodes de traitement d'un cancer à l'aide de composés de pyrrolopyrimidine substitués, compositions de ceux-ci
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1322318A (en) 1971-05-19 1973-07-04 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids and esters
US3838156A (en) * 1973-03-29 1974-09-24 Sterling Drug Inc Certain 2-substituted-6-(3 or 4-pyridyl)-nicotinic acid derivatives
US4072746A (en) * 1975-10-14 1978-02-07 Sterling Drug Inc. 3-Amino-5-(pyridinyl)-2(1H)-pyridinones
US4152434A (en) * 1976-04-22 1979-05-01 Hexachimie Morpholine containing imidzo[4,5-b]pyridines and use thereof
IT1156732B (it) * 1978-05-10 1987-02-04 Roussel Maestretti Spa Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione

Also Published As

Publication number Publication date
ZA811903B (en) 1982-04-28
JPS56150089A (en) 1981-11-20
US4294836A (en) 1981-10-13
KR830005216A (ko) 1983-08-03

Similar Documents

Publication Publication Date Title
DE3168433D1 (de) 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidin-4-one derivatives
PH20810A (en) Imidazo(4,5-b)and(4,5-c)pyridine derivatives having cardiotonic activity
IL64220A (en) Nicotinamide derivatives,their preparation and their use as herbicides
BE888088A (fr) Imidazopyridines, leur preparation et leur utilisation comme agents cardiotoniques
ZA811903B (en) Imidazo 4,5-b pyridine derivatives useful as cardiotonics and preparation
FI842459A7 (fi) Tetrahydropyridatsinonijohdannaisia, menetelmiä niiden valmistamiseksi sekä niiden käyttö.
FI793229A7 (fi) Pyrido/2,1-b/-kinatsolinoni- johdannaisia, niiden valmistus ja käyttö.
FI834665A7 (fi) Imidazo(1,5- a)pyridin-derivat.
ATE50259T1 (de) 1,6-naphthyridin-2(1h)-one brauchbar als kardiotonika.
BE887890A (fr) Derives de pyrazpolopyridine, leur preparation et leur utilisation comme agents cardiotoniques.
IL59538A0 (en) 3-substituted pyridine derivatives,their preparation and their use as funigicides
IT8021821A0 (it) Pirido [1,2-a] pirimidine sostituite
FI821035L (fi) Imidazo/1,2-a/pyrimidinderivat, deras framstaellning och anvaendning vid sjukvaord
FI834664A7 (fi) Substituoidut imidatso(1,5-a)pyridiinit.
FR2542742B1 (fr) Nouveaux derives de cyano-2 imidazo (4,5-b) pyridine. leur preparation et leur utilisation comme fongicides
FI864003A7 (fi) Pyrido /1,2-a/ pyrimidinderivat, foerfaranden foer framstaellning daerav och dessa innehaollande farmaceutiska kompositioner foer behandling av allergiska sjukdomar.
BE891493A (fr) Derives de 1,2-dihydro-5(pyridinyl) nicotinamide, leur preparation et leur utilisation comme agents cardiotoniques et intermediaires
DE3267918D1 (de) Pyrazolo(3,4-b)pyridine derivatives
DK33684D0 (da) Pyrazino (2',3'-3,4)pyrido(1,2-a)-indol-derivater
FI813757A7 (fi) Imidatso/4,5-b/pyridiinien ja - pyrimidiinien uusi valmistusmenetelmä.
MA21032A1 (fr) Derives d'imidazole , leur preparation et leur utilisation comme fongicides .
FR2536407B1 (fr) Nouveaux derives de la pyridone, leur preparation et leur utilisation comme colorants
BE879732A (fr) Derives d'acyl-1h-1,2,4-triazole, leur preparation et leur utilisation
BE880607A (fr) Derives de pyrazolo (1,5-c) quinazoline, leur preparation et leur utilisation
BE889599A (fr) Pyridinyl-amino-phenols, leur preparation et leur utilisation comme agents cardiotoniques